Adenocarcinoma of the Gastroesophageal Junction or Gastric
Showing 51 - 75 of 7,448
Metastatic HER2+ Advanced Breast Cancer, Breast Tumors, Gastric or Gastroesophageal Junction Adenocarcinoma (GEC) Trial in
Recruiting
- Metastatic HER2+ Advanced Breast Cancer
- +3 more
-
Harbin, Heilongjiang, China
- +4 more
Nov 15, 2022
Gastric Cancer, Peritoneal Metastases, Ascites, Malignant Trial in Hangzhou (Sintilimab in Combination With S-1/oxaliplatin With
Recruiting
- Gastric Cancer
- +2 more
- Sintilimab in Combination With S-1/oxaliplatin With nab-paclitaxel intraperitoneal infusion
- Blood samples, tumor biopsy specimens, ascites, and feces samples will be collected
-
Hangzhou, Zhejiang, ChinaZhejiang Cancer Hospital
Sep 18, 2023
Gastric Adenocarcinoma Trial (Pembrolizumab, Cisplatin, 5-FU)
Completed
- Gastric Adenocarcinoma
- Pembrolizumab
- +4 more
- (no location specified)
Aug 18, 2022
Carcinoma, Gastrointestinal Diseases, Stomach Cancer Trial (Anlotinib HCl capsule, Penpulimab Injection, XELOX)
Not yet recruiting
- Carcinoma
- +6 more
- Anlotinib hydrochloride capsule
- +2 more
- (no location specified)
Aug 8, 2022
Gastroesophageal Junction Adenocarcinoma, Stomach Tumors Trial in Barcelona (Avelumab addition to perioperative chemo in GC and
Recruiting
- Gastroesophageal Junction Adenocarcinoma
- Stomach Neoplasms
- Avelumab addition to perioperative chemotherapy in GC and GEJC
-
Barcelona, SpainVall d'Hebron Institute of Oncology
Oct 11, 2022
Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage II Gastric Cancer AJCC v8, Clinical Stage IIA Gastric Cancer AJCC v8
Not yet recruiting
- Clinical Stage I Gastric Cancer AJCC v8
- +24 more
- Capecitabine
- +6 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Mar 15, 2022
HER2-positive, Locally Advanced Solid Tumor, Immunotherapy Trial in Beijing (sintilimab, Trastuzumab, S-1 plus oxaliplatin)
Not yet recruiting
- HER2-positive
- +6 more
- sintilimab
- +2 more
-
Beijing, ChinaCancer Hospital & Institute, Chinese Academy of Medical Sciences
Mar 28, 2022
Gastric Cancer Trial in Xi'an (dietary supplement, biological, drug)
Recruiting
- Gastric Cancer
- Taurine
- +3 more
-
Xi'an, Shaanxi, ChinaTang-Du Hospital
Nov 7, 2023
Stomach Tumor Trial in Chengdu (Capeox regimen combined with Sintilimab and Bevacizumab)
Not yet recruiting
- Stomach Neoplasm
- Capeox regimen combined with Sintilimab and Bevacizumab
-
Chengdu, ChinaLiu Ming
Nov 28, 2022
Gastric Cancer, Gastric Adenocarcinoma, Effects of Chemo Trial in Taiwan (leucovorin, oxaliplatin, docetaxel, S-1)
Recruiting
- Gastric Cancer
- +3 more
- leucovorin, oxaliplatin, docetaxel, S-1
-
Kaohsiung, Taiwan
- +3 more
May 24, 2022
Metastatic HER2 Positive Gastroesophageal Junction Cancer Trial in La Jolla, Washington, Hackensack (CYNK-101, Pembrolizumab,
Recruiting
- Metastatic HER2 Positive Gastroesophageal Junction Cancer
- CYNK-101
- +6 more
-
La Jolla, California
- +2 more
Jul 12, 2022
Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma Trial in Guangzhou (Docetaxel,
Recruiting
- Metastatic Gastric Adenocarcinoma
- Metastatic Gastroesophageal Junction Adenocarcinoma
- Docetaxel
- +2 more
-
Guangzhou, Guangdong, ChinaThe Sixth Affiliated hosipital, Sun Yat-Sen University
Jan 20, 2022
Gastric Adenocarcinoma, Esophagus Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma Trial in France
Not yet recruiting
- Gastric Adenocarcinoma
- +2 more
- Trifluridine/Tipiracil
- +2 more
-
Amiens, France
- +20 more
Jul 26, 2022
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma Trial in Kashiwa (Trastuzumab Deruxtecan (T-DXd))
Recruiting
- Gastric Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
- Trastuzumab Deruxtecan (T-DXd)
-
Kashiwa, Chiba, JapanNational Cancer Center Hospital East
Apr 5, 2022
The Tumor Microenvironment for Locally Advanced Resectable
Recruiting
- Gastric Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
- non-intervention
-
Guangzhou, Guangdong, ChinaNanfang Hospital, Southern Medical University
Mar 24, 2022
Gastric Adenocarcinoma, Metastatic Adenocarcinoma of the Gastroesophageal Junction Trial in Germany (Ramucirumab, TAS 102)
Active, not recruiting
- Gastric Adenocarcinoma
- Metastatic Adenocarcinoma of the Gastroesophageal Junction
- Ramucirumab
- TAS 102
-
Frankfurt, Germany
- +4 more
Mar 2, 2022
Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage
Active, not recruiting
- Clinical Stage III Gastric Cancer AJCC v8
- +7 more
- Berzosertib
- +4 more
-
Duarte, California
- +30 more
Jan 7, 2023
Gastric Adenocarcinoma Trial in Guangzhou (Sintilimab, Ramucirumab, Cisplatin)
Active, not recruiting
- Gastric Adenocarcinoma
- Sintilimab
- +5 more
-
Guangzhou, ChinaSun Yat-sen University Cancer Center
Oct 10, 2022
Gastric Cancer, Gastroesophageal Junction Cancer Trial in China (Pembrolizumab, Placebo, Cisplatin)
Recruiting
- Gastric Cancer
- Gastroesophageal Junction Cancer
- Pembrolizumab
- +7 more
-
Beijing, Beijing, China
- +12 more
Aug 17, 2022
Gastric Cancer, Cancer of Stomach, Gastric Adenocarcinoma Trial in Woodville South (IMU-131, Irinotecan or Paclitaxel,
Not yet recruiting
- Gastric Cancer
- +5 more
- IMU-131
- +2 more
-
Woodville South, South Australia, AustraliaThe Queen Elizabeth Hospital
Apr 12, 2022